Aurobindo shares plunge on US import alert
This article was originally published in Scrip
Shares of Aurobindo Pharma were on a downward spiral on Indian bourses on 24 February over concerns that an import alert from the US FDA for products from one of its units could hurt the firm and trigger follow-on regulatory action in other markets.
You may also be interested in...
The US Food and Drug Administration has flagged more problems at Aurobindo, issuing another Form 483 to the company over one of its plants in southern India. This one, containing 11 observations, sharply faults quality controls.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.